文献速递细菌感染、耐药与抗菌药物

头孢洛林与万古霉素治疗耐甲氧西林金黄色葡萄球菌菌血症的匹配队列研究

Ceftaroline versus vancomycin for methicillin-resistant Staphylococcus aureus bacteraemia, a matched cohort study.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

这项回顾性匹配队列研究比较头孢洛林与万古霉素作为耐甲氧西林金黄色葡萄球菌菌血症初始靶向治疗的效果。45例头孢洛林治疗患者按1:2匹配83例万古霉素治疗患者。治疗失败复合终点两组相似(51.1% vs 57.8%,P=0.47),但头孢洛林组急性肾损伤更常见(51.1% vs 18.1%,P<0.001)。作者认为头孢洛林似乎是万古霉素的可行替代选择,但需更大规模研究提供明确结果并阐明肾毒性风险。

要点

  • 头孢洛林与万古霉素初始治疗MRSAB的治疗失败率无显著差异(51.1% vs 57.8%,P=0.47)。
  • 头孢洛林组急性肾损伤发生率高于万古霉素组(51.1% vs 18.1%,P<0.001)。
  • 多因素分析中仅年龄与治疗失败相关(aOR 1.06,95%CI 1.01-1.1,P=0.02)。

核心结论

  • 头孢洛林作为MRSAB初始治疗与万古霉素相比未带来结局改善,但似乎是万古霉素的可行替代选择。
  • 需要更大规模研究以提供明确结果并阐明肾毒性风险。

研究设计与样本

  • 回顾性匹配队列研究,2019-2021年连续纳入接受头孢洛林治疗的成年患者,按1:2比例与接受万古霉素的患者匹配。
  • 匹配因素为经食管超声心动图实施情况、Charlson合并症指数和年龄。
  • 主要结局为治疗失败复合终点,定义为90天死亡率或微生物学失败。

主要发现

  • 头孢洛林组45例与万古霉素组83例匹配,两组人口学和临床特征均衡。
  • 主要结局治疗失败在头孢洛林组与万古霉素组发生率相似(51.1%,23/45 vs 57.8%,48/83,P=0.47)。
  • 多因素分析中仅年龄与治疗失败相关(aOR 1.06,95%CI 1.01-1.1,P=0.02)。
  • 急性肾损伤在头孢洛林组更常见(51.1%,23/45 vs 18.1%,15/83,P<0.001)。

临床怎么用

  • 作者认为头孢洛林似乎是万古霉素的可行替代选择,但需更大规模研究提供明确结果并阐明肾毒性风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vancomycin remains the treatment-of-choice in MRSA bacteraemia (MRSAB) despite significant limitations. OBJECTIVE: To compare the effectiveness of ceftaroline and vancomycin monotherapy as the initial targeted therapy for MRSAB. METHODS: We conducted a retrospective matched cohort study. Consecutive adult patients treated with ceftaroline in the years 2019-2021 were matched in a 1:2 ratio with patients who received vancomycin. Controls were matched for performance of trans-oesophageal echocardiography, Charlson comorbidity index and age. The primary outcome was a composite of treatment failure, defined as 90-day mortality or microbiological failure. Descriptive statistics were used to compare the ceftaroline and vancomycin-treated groups. Univariate and multivariable binary logistic regression models were created using ceftaroline treatment as the exposure variable. RESULTS: Forty-five patients treated with ceftaroline for MRSAB were matched with 83 patients who received vancomycin. The groups were well balanced with regards to demographics and clinical characteristics. The primary outcome of treatment failure occurred at a similar rate in patients treated with ceftaroline or vancomycin (51.1%, 23/45% versus 57.8%, 48/83, respectively, P = 0.47). In the multivariable analysis, only age (aOR 1.06, 95% CI 1.01-1.1, P = 0.02) was associated with treatment failure. Acute kidney injury was more common among patients treated with ceftaroline (51.1%, 23/45% versus 18.1%, 15/83, P < 0.001). CONCLUSIONS: Ceftaroline was not associated with improved outcomes compared to vancomycin when given as initial treatment for MRSAB, however, it appears to be a viable alternative to vancomycin. Larger studies are needed to provide definitive results and to elucidate the risk of nephrotoxicity.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Bitterman R, Awwad A, Darawsha B, et al. Ceftaroline versus vancomycin for methicillin-resistant Staphylococcus aureus bacteraemia, a matched cohort study. J Antimicrob Chemother. 2025. PMID: 39871614. doi:10.1093/jac/dkaf009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。